Status:
COMPLETED
Optimization of the Patient Care Pathway in Immuno-oncology
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study compares the care pathway of melanoma patients treated by immunotherapy in two ambulatory care structures. The aim is to measure if a care structure specialized in immuno-oncology could rat...
Eligibility Criteria
Inclusion
- Patient with advanced (unresectable melanoma (stage III)) or metastatic (stage IV) melanoma and starting an Immune Checkpoint Inhibitor treatment (Monotherapy or Combination Therapy)
- Patient starting first cycle of Immune Checkpoint Inhibitor treatment in an ambulatory care structure
- Treatment which can be delayed for 7 days or more
- Age \> or = 18 years old
- Patient with a phone and/or computer equipment
- Patient affiliated to the french social security system
- Patient must provide written informed consent prior to any study-specific procedure or assessment
Exclusion
- Patient with diagnosis other than advanced melanoma
- Patient who must receive a treatment other than Immune Checkpoint Inhibitor
- Treatment administered during a conventional hospital stay (period of more than 24 hours)
- Patient with no caregiver
- Pregnant or breastfeeding women
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient protected by law
Key Trial Info
Start Date :
December 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 19 2021
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT03329755
Start Date
December 26 2017
End Date
February 19 2021
Last Update
February 24 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Saint André, CHU de Bordeaux
Bordeaux, France, 33076
2
Institut claudius regaud IUCT ONCOPOLE
Toulouse, France, 31059